Home › Drug Codes › J Codes › J1449 · ROLVEDON
Updated July 1st, 2026

ROLVEDON J Code: J1449

Injection, eflapegrastim-xnst, 0.1 mg

Login to unlock all benchmarks

Q4 2026 Medicare Payment Limit for J1449, effective October 1, 2026: $37.421 per HCPCS billing unit, down 3.0% from $38.562. From CMS's final file.

?
Medicare Payment Limit ?
$38.562
/ HCPCS billing unit · Q3 2026
APC Payment Limit ?
$38.562
/ HCPCS billing unit · APC 9114
ASP ?
$•••.••
Login to view
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
2
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Injection, eflapegrastim-xnst, 0.1 mg
HCPCS Added Date April 1, 2023
Manufacturer Assertio Pharmaceuticals
Route of Administration Subcutaneous
Generic Status Single-Source; Branded
Dosage Type Single-Dose
Dosage Form Injection, Solution

About ROLVEDON

Rolvedon is a medication aligned to the HCPCS J Code: J1449 for billing, pricing, and reimbursement purposes in the United States. This Oncology Colony Stimulating Factor medication is administered via the subcutaneous route and manufactured by Assertio Pharmaceuticals.

According to CMS Drug Use Information: Eflapegrastim is a man-made version of a certain natural substance made by your body. It is used to help your body make more white blood cells. White blood cells are important to help you fight off infections. Eflapegrastim is given to people whose ability to make white blood cells is reduced due to chemotherapy.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
76961-0101-01 Rolvedon Spectrum Pharmaceuticals, Inc. 132 13.2 MG / 0.6 ML
82497-0132-01 Rolvedon Assertio Specialty Pharmaceuticals, LLC 132 13.2 MG / 0.6 ML
Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

ROLVEDON Pricing & Reimbursement

J1449 Private Payer Reimbursement
$24.08 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna

Historical Graphing and Billing Calculator

per HCPCS unit
As of Q3 2026

ROLVEDON Claims Performance

Claims from Jan 2026 – Aug 2026
Claim Denial Rate 10.45%
Avg. Days to File 6.5days
Avg. Days to Pay 20.9days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J1449 claims analytics on FocalPoint →
OnPoint Oncology

ROLVEDON CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
96401 Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic
JW / JZ modifiers apply

CMS has identified Rolvedon (J1449) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

ROLVEDON Medically Unlikely Edits (MUE)

The most billing units of J1449 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 0.1 mg.

Practitioner Office & Hospital Outpatient
132 units / day
= 13.2 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

mg Enter a dose to see how many billing units it is and whether it is under the limit.

ROLVEDON Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

non-myeloid malignancies with febrile neutropenia risk
Drug Class
Granulocyte Colony-Stimulating Factor [CS]Increased Myeloid Cell Production [PE]Leukocyte Growth Factor [EPC]

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.

Frequently Asked Questions

Is there an available Rolvedon billing and coding guide?
Billing and coding information for ROLVEDON can be found through Assertio Pharmaceuticals. Visit Here →
Are there any available Rolvedon patient assistance programs?
Rolvedon patient assistance information can be found through ACCESS4ME at the URL: https://www.access4me.com/patient-support/ Visit Here →
Where can I find Rolvedon prescribing information?
ROLVEDON prescribing information can be found at the link below: Visit Here →
Where can I find Rolvedon side effect information?
Our team has not yet identified a source of side effects information for ROLVEDON. Please check back in a few weeks.
Does billing ROLVEDON require JZ/JW wastage modifiers?
CMS has identified ROLVEDON(J1449) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.